OpenResearchAlpha

bioRxiv · 17 Nov 2026

In silico designed small molecule targets misfolded TDP-43 to rescue function and ALS pathology

Marcela Kokesh-index 6, Devi Supriya Korumilli, Vanessa Seawright, Shruti Arya, Annika van Hummel, Miheer Sabale, Md. Anzarul Haque, Naomi Moreno, Agenor Limon, Pritam Ganguly, Eric Shao, Yazi D. Ke, Rakez Kayed, Joan-Emma Shea, Ambuj Singh, Lewis Whitehead, Catherine Planey, Vidhu Mathurh-index 12

0
Citations
no database records one yet
0
Citations in 2026
so far
12
Leading author's h-index
Vidhu Mathur, in QAI's scholar index
0
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

The DNA/RNA binding protein TARDBP or TDP-43 is a key driver of pathology in Amyotrophic Lateral Sclerosis (ALS), a motor neuron disease with no known cure. In >97% of sporadic ALS patients, nuclear TDP-43 in motor neurons mislocalizes and aggregates in the cellular cytoplasm (gain-of-function). A parallel reduction in nuclear TDP-43 in ALS patients leads to a loss-of-function in mRNA binding and splicing regulation. Using our machine learning platform, we discovered ACE-339, a novel, orally bioavailable small molecule that disrupts insoluble TDP-43 aggregates. Using in vitro, in vivo and in silico models, we show that ACE-339 directly targets aggregated forms of TDP-43. ACE-339 interacts directly with TDP-43 hexamers, disaggregates recombinant TDP-43 and rescues both gain- and loss-of-function phenotypes of TDP-43 in cells. ACE-339 functionally rescues TDP-43 dependent mis-splicing and synaptic activity. Lastly, ACE-339 rescues disease associated phenotypes in two independent mouse models of TDP-43 pathology. In addition, we now have a catalog of TDP-43 disaggregating compounds that are being developed further to be tested in clinical trials in patients with ALS and other TDP-43 proteinopathies.

Neuroscience

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Vidhu Mathur has the highest h-index among the authors (12).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (18)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (0)

What it cites, from open citation data, with Crossref's record of each.

No references in the open citation data yet.